Trust the science

Evira has been used by thousands of families for years with excellent results. The data shows that we significantly outperform traditional treatments.

Significantly greater relative weight loss

Our studies show that there is a significant difference in relative weight loss after one year of treatment with Evira compared to traditional treatment. The treatment with Evira is also less resource-intensive than the treatments that form the basis of the results presented under USPSTF in the figure.

The figure below shows the reduction of overweight in WHO BMI SDS during a first year of treatment in randomly selected patients. BMI SDS is a relative measure of obesity used for children.

Signifikant större relativ viktminskning

Comparison between treatment results in WHO BMI SDS after one year of treatment with Evira and traditional treatment according to the Child Obesity Register in Sweden (BORIS) as well as results presented in a meta-study for children who received at least 26 hours of professional support over a year compiled by

United States Preventive Services Task Force (USPSTF).

Significantly better
than traditional treatment

Evira has been validated in clinical studies and used in clinical practice for several years with very good results.

Happier families

In one of our studies, 78% of families were satisfied with the treatment results after one year of treatment with Evira compared to only 11% among parents in traditional treatment.

Fewer canceled visits

Among patients treated with Evira, the number of canceled visits decreased by 45% during a

six-month period, where only

40% of patients canceled at least one visit, compared to 85% with traditional treatment.

Lower cost

Evira has unmatched results in clinical studies for children where no drugs or surgery were used. Those who received treatment with Evira had, on average, twice as good a treatment effect compared to corresponding groups who received traditional treatment.

Research about Evira

Evira has been evaluated clinically and in a research context in various forms for several years. Treatment with Evira gives, on average, twice as good an effect compared to traditional treatment.

One-year study in clinical practice

In our latest one-year study together with prominent researchers from Karolinska Institutet, the first 107 patients at the Martina Children's Hospital Center for Weight Health were able to use Evira's platform and treatment method for a year. A matched control group of 321 patients was randomly selected from the national quality registry BORIS who received traditional childhood obesity treatment during the same time period. The intervention group using Evira had a relative weight loss of 0.30 WHO BMI SDS units, compared to the control group which averaged 0.15 WHO BMI SDS units.

Resultat från ettårsstudien gjord i samarbete med KI.

Mean change in WHO BMI SDS for Evira patients (dark gray) and the control group of BORIS patients (light gray) after 1 year of treatment divided by sex, age and degree of obesity in the 1-year study.

In addition to being able to see twice as good treatment results with Evira compared to traditional treatment, we were able to see a big effect on teenagers - a treatment group that has been very difficult to reach before with traditional treatment.

Long-term effects of digital obesity treatment: Three-year follow-up study

This study from Karolinska Institutet, following up on our previous one-year study and based on the same cohort, shows that the relative weight reduction achieved by children and adolescents using the digital treatment tool Evira after one year of treatment was maintained for up to three years.

Patients treated with the digital tool experienced more than twice the reduction in BMI SDS (degree of overweight) and a higher proportion achieved remission from obesity compared to those receiving conventional standard care.

Mean change in BMI Z-score for patients in the digi-physical treatment group (dotted line) and the standard treatment group (dashed line) over three years, adjusted for sex, age, and degree of obesity at treatment initiation.

The three-year pragmatic clinical study, which followed 428 children and adolescents aged 4–17 years, compared two groups: one treated with the digital tool Evira (n=107) and a control group receiving conventional standard

care (n=321).

The prevalence of disordered eating behaviors and eating disorder diagnoses was examined in the group receiving digital treatment throughout the entire treatment period and for one year after completion. During follow-up, three patients showed signs of disordered eating behavior, all of whom were already in contact with specialist psychiatric care. No patient was diagnosed with an eating disorder during the study.

Key findings:

Patients using the digital tool lost twice as much relative weight as the control group after one year and maintained their weight loss for up to three years.
Those treated with the digital tool were 70% more likely to achieve remission, i.e reach a BMI below the obesity threshold, compared to those receiving standard treatment.
Treatment adherence was higher in the digital tool group, with significantly fewer patients dropping out compared to standard treatment.
No patient using the digital tool developed an eating disorder diagnosis during treatment or in the year that followed.

Feasibility study

During Evira’s initial phase, the platform was tested in a small feasibility study at three clinics over a period of six months. The study showed a good treatment effect after six months compared to traditional treatment, and showed that patients and therapists were very satisfied with the platform.

Förändring av BMI SDS i feasibility-studien.

Change in WHO BMI SDS from baseline to follow-up at three and six months for intervention and control groups in the feasibility study.

Almost everyone in the intervention group who used Evira reported that Evira helped them reach their treatment goals, and that it was easier to get in touch with health care providers at the clinic. The families who used Evira were significantly more satisfied with the treatment results compared to the control group.

Doctoral thesis by Linnea Johansson
Linnea Johansson, Ph. D, has researched mobile health interventions with Evira as the main focus in his doctoral thesis . She brings up several important lessons about how to think about digital treatment and analyzes what worked and what didn't work during Evira's development period. She concludes by stating that digital health interventions together with clinical visits, such as Evira, provide a better treatment effect than behavioral treatment alone. Linnea also places great emphasis on the importance of technical maturity of digital systems, as well as the importance of teaching clinical staff how treatment with the help of digital support systems should be carried out.

EurEvira - international multicenter study
(ongoing)

EurEvira is an international multicenter study that is ongoing in several European countries to evaluate how Evira together with local childhood obesity treatment works in countries other than Sweden.

The study is currently being conducted at the following sites in Europe.